Leaving INTR@PID website

You are leaving INTR@PID Clinical Trials page. This link will take you to a website where our Terms of Use do not apply. Merck KGaA has no control over the contents and policies of these sites or resources, and accepts no responsibility for your use of them.

Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S., Puerto Rico and Canada who are interested in information on Clinical Research and EMD Serono sponsored clinical trials.

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S., Puerto Rico and Canada and have read and understood this disclaimer.

About Us

Merck KGaA, Darmstadt, Germany, and GSK have formed a global alliance to jointly develop and commercialize bintrafusp alfa (M7824), an investigational bifunctional fusion protein designed to target both TGF-β and PD-L1. Together, we are inspired by curiosity, science, and, most importantly, patients, combining a creative approach with our relentless drive to transform cancer research.
 

Together, as leaders of this novel immunotherapy class, we aim to drive innovation in cancer care. Jointly, we are working to accelerate bintrafusp alfa clinical development programs to improve patient opportunity. Bintrafusp alfa is currently in clinical development, including potential registration studies, for multiple difficult-to-treat cancers.